Merck & Co gets in on the bispecific act
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
SITC 2024 – Arcus springs a TIGIT surprise
Reports of Arc-10's failure are greatly exaggerated, the company argues.
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
Reports of Arc-10's failure are greatly exaggerated, the company argues.
